President Donald Trump announced new tariffs on generic drugs set to take effect in 2028, as part of a broader strategy to reduce dependence on foreign pharmaceutical supplies and support domestic drug manufacturing. The move is expected to impact the availability and pricing of generic medications in the United States.

Policy Shift and Domestic Production Goals

The tariffs. Which will apply to a range of generic drugs imported from countries such as India and China, aim to encourage pharmaceutical companies to manufacture medications within the U.S. administration. According to the U.S. Department of Commerce. The policy is part of a larger initiative to strengthen the domestic pharmaceutical supply chain, which has been identified as a national security concern following the pandemic.

Commerce Secretary Wilbur Ross stated that the tariffs are intended to incentivize companies to establish or expand manufacturing facilities in the U.S. The administration has already provided tax incentives and grants to pharmaceutical firms under its “Made in America” initiative, which has seen a 12% increase in domestic drug production since its launch in 2021.

Industry and Consumer Reactions

Reactions from the pharmaceutical industry have been mixed — the Generic Pharmaceutical Association (GPhA) expressed concern that the tariffs could lead to higher drug prices for American consumers. According to GPhA. Over 90% of generic drugs sold in the U.S. are produced abroad, with India and China accounting for more than 70% of that total.

“While we support the goal of strengthening domestic manufacturing, the timing and structure of these tariffs could have unintended consequences, including reduced access to affordable medications,” said GPhA spokesperson Karen Szuminsky. Consumer advocacy groups have echoed these concerns, noting that the average American household spends $2,500 annually on prescription drugs, with generic medications often being the most affordable option.

International and Political Implications

The announcement has also drawn attention from international trade partners, particularly in India and China, where the pharmaceutical industry is a major economic sector, though Indian trade officials have called the move “disproportionate,” arguing that it undermines the role of India as a trusted supplier of generic drugs globally. China, meanwhile, has warned that the tariffs could lead to retaliatory measures against U.S. exports.

Politically, the tariffs have sparked debate within Congress. Some lawmakers from both parties have criticized the move as an overreach, while others have praised it as a necessary step to protect national security. According to a recent survey by the Pew Research Center, 58% of Americans believe the U.S. should rely more on domestically produced drugs, while 37% are concerned about potential price increases.

The Trump administration has emphasized that the tariffs will not take effect immediately and will be phased in over the next three years, allowing time for the industry to adjust. In the meantime, the administration is working with pharmaceutical companies to simplify regulatory processes and reduce the time it takes to bring new drugs to market domestically.